For most investigational therapies, the path to a pediatric trial runs through an adult trial first in order to afford additional protection to children. Sponsors establish an initial safety and dosing profile in adults, then adapt the protocol for younger populations. Gene therapies targeting conditions where patients do not survive to adulthood cannot follow this […]
Many sponsors are reaching for AI tools throughout the informed consent process, from formatting documents to drafting participant-facing language. Most don’t yet have a clear way to sort what they’re working with. An automated tool that checks reading grade level sits in a different category than a large language model drafting consent language or answering […]
Gene therapy holds promise for patients with genetic diseases, yet it also represents a fundamental departure from the paradigm most drug-development professionals were trained in. The therapeutic agents and patient populations are different, and the regulatory and ethical framework is unlike anything most sponsors have navigated before. Encountering these differences for the first time at […]
greenbutterfly | Adobe Stock “The regulatory climate in the U.S. remains unpredictable, leaving some companies with the kind of surprise rejections and delays that make risky biotech investments even riskier,” notes a recent industry outlook. Emerging biotechs operate in an environment where speed is a baseline expectation, and growing global competition adds pressure to move […]
May 20-23, 2018 Arlington, VA
Feb 25-28 2018 Orlando, FL